Open Access

Ergosterol limits osteoarthritis development and progression through activation of Nrf2 signaling

  • Authors:
    • Dawei Cai
    • Huyong Yan
    • Jun Liu
    • Sichun Chen
    • Longhai Jiang
    • Xiaoxu Wang
    • Jian Qin
  • View Affiliations

  • Published online on: January 8, 2021     https://doi.org/10.3892/etm.2021.9627
  • Article Number: 194
  • Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteoarthritis (OA) is a common joint disorder characterized by progressive articular cartilage degeneration and destruction and results in gradual disability among middle‑aged and elderly patients. Our previous study demonstrated that depletion of nuclear factor erythroid 2‑related factor 2 (Nrf2) exacerbated cartilage erosion in an OA model and that activation of the Nrf2 pathway could counter this process. As a downstream target of Nrf2, heme oxygenase (HO) degrades heme to free iron, biliverdin and carbon monoxide (CO), which protects against oxidative stress. Ergosterol (ER), which is extracted from fungi, is a newly discovered Nrf2 activator and displayed efficacy against myocardial injury. The present study aimed to investigate the potential protective effects of ER against cartilage damage during OA. Primary mouse chondrocytes were treated with ER for in vitro assays. Furthermore, mice that underwent destabilization of the medial meniscus surgery were orally administered with ER. Western blotting suggested that ER increased protein expression of Nrf2 and HO‑1 in primary chondrocytes and articular cartilage from knee joints. Cartilage damage in knee joints was significantly reduced by ER treatment. Western blotting and PCR analysis confirmed that ER could also suppress the expression of MMP‑9 and MMP‑13 in vivo and in vitro. The present findings suggested that ER effectively alleviated cartilage degradation and that activation of the Nrf2‑heme oxygenase 1 pathway may play a role in ER‑mediated cartilage protection against OA.
View Figures
View References

Related Articles

Journal Cover

March-2021
Volume 21 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cai D, Yan H, Liu J, Chen S, Jiang L, Wang X and Qin J: Ergosterol limits osteoarthritis development and progression through activation of Nrf2 signaling. Exp Ther Med 21: 194, 2021
APA
Cai, D., Yan, H., Liu, J., Chen, S., Jiang, L., Wang, X., & Qin, J. (2021). Ergosterol limits osteoarthritis development and progression through activation of Nrf2 signaling. Experimental and Therapeutic Medicine, 21, 194. https://doi.org/10.3892/etm.2021.9627
MLA
Cai, D., Yan, H., Liu, J., Chen, S., Jiang, L., Wang, X., Qin, J."Ergosterol limits osteoarthritis development and progression through activation of Nrf2 signaling". Experimental and Therapeutic Medicine 21.3 (2021): 194.
Chicago
Cai, D., Yan, H., Liu, J., Chen, S., Jiang, L., Wang, X., Qin, J."Ergosterol limits osteoarthritis development and progression through activation of Nrf2 signaling". Experimental and Therapeutic Medicine 21, no. 3 (2021): 194. https://doi.org/10.3892/etm.2021.9627